Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CYBN NASDAQ:HYPD NASDAQ:PBYI NASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYBNCybin$7.41-0.6%$7.77$4.81▼$13.88$170.72M0.69283,758 shs32,901 shsHYPDHyperion DeFi$14.13+9.6%$5.80$0.85▼$124.80$40.69M2.472.31 million shs259,509 shsPBYIPuma Biotechnology$3.52+1.6%$3.39$2.23▼$4.13$174.70M1.29412,458 shs45,153 shsTILInstil Bio$24.27+1.7%$24.82$9.85▼$92.00$158.27M2.15195,096 shs41,401 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYBNCybin-0.13%-2.23%-10.66%+0.13%+1,921.68%HYPDHyperion DeFi+7.15%-19.24%+428.28%+1,104.67%-84.94%PBYIPuma Biotechnology+0.29%-3.62%+3.28%+20.14%-5.46%TILInstil Bio-2.53%+1.88%-30.27%+56.01%+76.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYBNCybin2.4812 of 5 stars3.60.00.00.02.10.81.3HYPDHyperion DeFi0.6141 of 5 stars1.05.00.00.01.10.00.6PBYIPuma Biotechnology4.2056 of 5 stars3.52.00.00.02.64.23.1TILInstil Bio3.4145 of 5 stars3.52.00.00.03.33.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYBNCybin 3.25Buy$85.001,050.20% UpsideHYPDHyperion DeFi 2.00Hold$2.00-84.38% DownsidePBYIPuma Biotechnology 3.00Buy$7.00100.00% UpsideTILInstil Bio 3.00Buy$119.00398.22% UpsideCurrent Analyst Ratings BreakdownLatest HYPD, CYBN, TIL, and PBYI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.006/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$125.00 ➝ $125.006/2/2025TILInstil BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/22/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$110.00 ➝ $105.005/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYBNCybinN/AN/AN/AN/A$10.83 per shareN/AHYPDHyperion DeFi$60K614.40N/AN/A($695.52) per share-0.02PBYIPuma Biotechnology$230.50M0.75$0.86 per share4.05$1.88 per share1.86TILInstil BioN/AN/AN/AN/A$25.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYBNCybin-$57.88M-$3.88N/AN/AN/AN/A-37.58%-36.59%N/AHYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.774.519.21N/A16.37%49.35%18.25%7/30/2025 (Estimated)TILInstil Bio-$74.14M-$11.97N/AN/AN/AN/A-45.52%-29.23%8/12/2025 (Estimated)Latest HYPD, CYBN, TIL, and PBYI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025N/ATILInstil Bio-$1.72N/AN/AN/AN/AN/A8/7/2025Q2 2025PBYIPuma Biotechnology$0.11N/AN/AN/A$52.00 millionN/A5/19/2025Q1 2025HYPDHyperion DeFi-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/13/2025Q1 2025TILInstil Bio-$2.02-$4.32-$2.30-$4.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYBNCybinN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYBNCybinN/A24.2424.24HYPDHyperion DeFiN/A0.340.34PBYIPuma Biotechnology0.111.531.43TILInstil Bio0.5830.3330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYBNCybin17.94%HYPDHyperion DeFi25.84%PBYIPuma Biotechnology61.29%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipCYBNCybin15.00%HYPDHyperion DeFi7.10%PBYIPuma Biotechnology23.30%TILInstil Bio46.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYBNCybin5023.02 million17.96 millionNot OptionableHYPDHyperion DeFi402.88 million2.68 millionOptionablePBYIPuma Biotechnology20049.63 million38.07 millionOptionableTILInstil Bio4106.56 million3.51 millionNo DataHYPD, CYBN, TIL, and PBYI HeadlinesRecent News About These CompaniesUS FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumoursJuly 4, 2025 | pharmabiz.comPInstil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...July 3, 2025 | manilatimes.netMInstil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - NasdaqJuly 3, 2025 | nasdaq.comInstil Bio Shares Climb After FDA Clears Tumor Treatment ApplicationJuly 2, 2025 | marketwatch.comInstil Bio stock jumps after FDA clearance of IND applicationJuly 2, 2025 | in.investing.comInstil Bio Shares Surge on FDA Clearance for Investigational Cancer TherapyJuly 2, 2025 | msn.comInstil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid TumorsJuly 2, 2025 | globenewswire.comInstil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should KnowJune 20, 2025 | zacks.comWall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a BetJune 16, 2025 | zacks.comInstil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody ProgramJune 11, 2025 | globenewswire.comAre You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great ChoiceJune 4, 2025 | zacks.comInstil Bio appoints new Chief Medical OfficerJune 4, 2025 | uk.investing.comInstil Bio appoints Jamie Freedman as Chief Medical OfficerJune 2, 2025 | msn.comInstil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy DevelopmentJune 2, 2025 | quiverquant.comQInstil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerJune 2, 2025 | globenewswire.comInstil Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 30, 2025 | globenewswire.comInstil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?May 29, 2025 | zacks.comWall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to TradeMay 29, 2025 | zacks.comInstil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF SuccessMay 25, 2025 | seekingalpha.comInstil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ...May 25, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!SoundHound’s AI Growth Story Is Just Getting StartedBy Gabriel Osorio-Mazilli | June 16, 2025View SoundHound’s AI Growth Story Is Just Getting StartedForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffIran Conflict Fuels Fertilizer Stocks’ Bullish SetupBy Gabriel Osorio-Mazilli | June 16, 2025View Iran Conflict Fuels Fertilizer Stocks’ Bullish SetupThe Boring Is Beautiful Portfolio: 3 Stocks for a Worried WorldBy Jeffrey Neal Johnson | June 22, 2025View The Boring Is Beautiful Portfolio: 3 Stocks for a Worried WorldHYPD, CYBN, TIL, and PBYI Company DescriptionsCybin NYSE:CYBN$7.41 -0.05 (-0.62%) As of 10:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Hyperion DeFi NASDAQ:HYPD$14.13 +1.24 (+9.62%) As of 10:10 AM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Puma Biotechnology NASDAQ:PBYI$3.52 +0.06 (+1.59%) As of 10:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Instil Bio NASDAQ:TIL$24.27 +0.40 (+1.68%) As of 10:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
